Skip to main content

Advertisement

SpringerLink
Log in

Network-based drug repurposing identifies small molecule drugs as immune checkpoint inhibitors for endometrial cancer

  • Original Article
  • Published:
Molecular Diversity Aims and scope Submit manuscript

Abstract

Endometrial cancer (EC) is the 6th most common cancer in women around the world. Alone in the United States (US), 66,200 new cases and 13,030 deaths are expected to occur in 2023 which needs the rapid development of potential therapies against EC. Here, a network-based drug-repurposing strategy is developed which led to the identification of 16 FDA-approved drugs potentially repurposable for EC as potential immune checkpoint inhibitors (ICIs). A network of EC-associated immune checkpoint proteins (ICPs)-induced protein interactions (P-ICP) was constructed. As a result of network analysis of P-ICP, top key target genes closely interacting with ICPs were shortlisted followed by network proximity analysis in drug–target interaction (DTI) network and pathway cross-examination which identified 115 distinct pathways of approved drugs as potential immune checkpoint inhibitors. The presented approach predicted 16 drugs to target EC-associated ICPs-induced pathways, three of which have already been used for EC and six of them possess immunomodulatory properties providing evidence of the validity of the strategy. Classification of the predicted pathways indicated that 15 drugs can be divided into two distinct pathway groups, containing 17 immune pathways and 98 metabolic pathways. In addition, drug–drug correlation analysis provided insight into finding useful drug combinations. This fair and verified analysis creates new opportunities for the quick repurposing of FDA-approved medications in clinical trials.

Graphical abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Data availability

The supplementary data Tables and figures are provided.

Code availability

The coding files will be provided on demand.

References

  1. Rodrigues R, Duarte D, Vale N (2022) Drug repurposing in cancer therapy: influence of patient’s genetic background in breast cancer treatment. Int J Mol Sci. https://doi.org/10.3390/IJMS23084280

    Article  PubMed  PubMed Central  Google Scholar 

  2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108. https://doi.org/10.3322/CAAC.21262

    Article  PubMed  Google Scholar 

  3. Zou Y, Xu Y, Chen X, Zheng L (2023) Advances in the application of immune checkpoint inhibitors in gynecological tumors. Int Immunopharmacol 117:109774. https://doi.org/10.1016/j.intimp.2023.109774

    Article  CAS  PubMed  Google Scholar 

  4. Lin CK, Liu ST, Wu ZS, Wang YC, Huang SM (2021) Mechanisms of cisplatin in combination with repurposed drugs against human endometrial carcinoma cells. Life (Basel, Switzerland) 11(2):1–18. https://doi.org/10.3390/LIFE11020160

    Article  Google Scholar 

  5. Gómez-Raposo C, Merino Salvador M, Aguayo Zamora C, García de Santiago B, Casado Sáenz E (2021) Immune checkpoint inhibitors in endometrial cancer. Crit Rev Oncol Hematol 161:103306. https://doi.org/10.1016/J.CRITREVONC.2021.103306

    Article  PubMed  Google Scholar 

  6. Ahmed F et al (2022) A comprehensive review of artificial intelligence and network based approaches to drug repurposing in Covid-19. Biomed Pharmacother 153:113350. https://doi.org/10.1016/J.BIOPHA.2022.113350

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Ahmed F, Samantasinghar A, Soomro AM (2023) A systematic review of computational approaches to understand cancer biology for informed drug repurposing. J Biomed Inform. https://doi.org/10.1016/j.jbi.2023.104373

    Article  PubMed  Google Scholar 

  8. Ahmed F et al (2023) Drug repurposing for viral cancers: a paradigm of machine learning, deep learning, and virtual screening-based approaches. J Med Virol. https://doi.org/10.1002/jmv.28693

    Article  PubMed  Google Scholar 

  9. Samantasinghar A et al (2023) A comprehensive review of key factors affecting the efficacy of antibody drug conjugate. Biomed Pharmacother 161:114408. https://doi.org/10.1016/j.biopha.2023.114408

    Article  CAS  PubMed  Google Scholar 

  10. Asif A et al (2021) Microphysiological system with continuous analysis of albumin for hepatotoxicity modeling and drug screening. J Ind Eng Chem 98:318–326. https://doi.org/10.1016/J.JIEC.2021.03.035

    Article  CAS  Google Scholar 

  11. Ahmed F et al (2022) Drug repurposing in psoriasis, performed by reversal of disease-associated gene expression profiles. Comput Struct Biotechnol J 20:6097–6107. https://doi.org/10.1016/J.CSBJ.2022.10.046

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ahmed F et al (2022) SperoPredictor: an integrated machine learning and molecular docking-based drug repurposing framework with use case of COVID-19. Front Public Health. https://doi.org/10.3389/FPUBH.2022.902123

    Article  PubMed  PubMed Central  Google Scholar 

  13. Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F (2020) Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov 6(1):1–18. https://doi.org/10.1038/s41421-020-0153-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Shiravand Y et al (2022) Immune checkpoint inhibitors in cancer therapy. Curr Oncol 29(5):3044–3060. https://doi.org/10.3390/curroncol29050247

    Article  PubMed  PubMed Central  Google Scholar 

  15. Hirschhorn D et al (2023) T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants. Cell 186(7):1432-1447.e17. https://doi.org/10.1016/j.cell.2023.03.007

    Article  CAS  PubMed  Google Scholar 

  16. Sharma R, Kaur G, Bansal P, Chawla V, Gupta V (2022) Bioinformatics paradigms in drug discovery and drug development. Curr Top Med Chem 23(7):579–588. https://doi.org/10.2174/1568026623666221229113456

    Article  CAS  Google Scholar 

  17. Maiorano BA, Maiorano MFP, Cormio G, Maglione A, Lorusso D, Maiello E (2022) How immunotherapy modified the therapeutic scenario of endometrial cancer: a systematic review. Front Oncol. https://doi.org/10.3389/fonc.2022.844801

    Article  PubMed  PubMed Central  Google Scholar 

  18. Musacchio L et al (2020) Immune checkpoint inhibitors: a promising choice for endometrial cancer patients? J Clin Med 9(6):1721. https://doi.org/10.3390/JCM9061721

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Napolitano F et al (2013) Drug repositioning: a machine-learning approach through data integration. J Cheminform 5(6):1–9. https://doi.org/10.1186/1758-2946-5-30/FIGURES/5

    Article  Google Scholar 

  20. Yuan M et al (2022) A gene co-expression network-based drug repositioning approach identifies candidates for treatment of hepatocellular carcinoma. Cancers (Basel) 14(6):1573. https://doi.org/10.3390/CANCERS14061573/S1

    Article  CAS  PubMed  Google Scholar 

  21. Zhou Y, Wang F, Tang J, Nussinov R, Cheng F (2020) Artificial intelligence in COVID-19 drug repurposing. Lancet Digit Health 2(12):e667–e676. https://doi.org/10.1016/S2589-7500(20)30192-8

    Article  PubMed  PubMed Central  Google Scholar 

  22. Yang S, Fu C, Lian X, Dong X, Zhang Z (2019) Understanding human-virus protein-protein interactions using a human protein complex-based analysis framework. mSystems. https://doi.org/10.1128/MSYSTEMS.00303-18/SUPPL_FILE/MSYSTEMS.00303-18-SF006.PDF

    Article  PubMed  PubMed Central  Google Scholar 

  23. Liu C et al (2020) Computational network biology: data, models, and applications. Phys Rep 846:1–66. https://doi.org/10.1016/J.PHYSREP.2019.12.004

    Article  Google Scholar 

  24. Firoozbakht F, Rezaeian I, Rueda L, Ngom A (2022) Computationally repurposing drugs for breast cancer subtypes using a network-based approach. BMC Bioinform 23(1):1–36. https://doi.org/10.1186/S12859-022-04662-6/TABLES/2

    Article  CAS  Google Scholar 

  25. Vitali F et al (2016) A network-based data integration approach to support drug repurposing and multi-target therapies in triple negative breast cancer. PLoS ONE 11(9):e0162407. https://doi.org/10.1371/JOURNAL.PONE.0162407

    Article  PubMed  PubMed Central  Google Scholar 

  26. Fang J et al (2020) Network-based translation of GWAS findings to pathobiology and drug repurposing for Alzheimer’s disease. medRxiv. https://doi.org/10.1101/2020.01.15.20017160

    Article  PubMed  PubMed Central  Google Scholar 

  27. Cheng F et al (2018) Network-based approach to prediction and population-based validation of in silico drug repurposing. Nat Commun 9(1):1–12. https://doi.org/10.1038/s41467-018-05116-5

    Article  CAS  Google Scholar 

  28. Cheng F et al (2019) A genome-wide positioning systems network algorithm for in silico drug repurposing. Nat Commun 10(1):1–14. https://doi.org/10.1038/s41467-019-10744-6

    Article  CAS  Google Scholar 

  29. Wang Y et al (2022) Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts. J Hematol Oncol 15(1):1–53. https://doi.org/10.1186/S13045-022-01325-0

    Article  CAS  Google Scholar 

  30. Vafaei S et al (2022) Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. Cancer Cell Int 22(1):1–27. https://doi.org/10.1186/s12935-021-02407-8

    Article  CAS  Google Scholar 

  31. Naimi A et al (2022) Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal 20(1):1–31. https://doi.org/10.1186/S12964-022-00854-Y

    Article  Google Scholar 

  32. Khalifa R, Elsese N, El-Desouky K, Shaair H, Helal D (2021) Immune checkpoint proteins (PD-L1 and CTLA-4) in endometrial carcinoma: prognostic role and correlation with CD4+/CD8+ tumor infiltrating lymphocytes (TILs) ratio. J Immunoassay Immunochem 43(2):192–212. https://doi.org/10.1080/15321819.2021.1981377

    Article  CAS  PubMed  Google Scholar 

  33. Hagberg A, Swart P, Schult J, Daniel A (2008) Exploring network structure, dynamics, and function using networkx (conference) | OSTI.GOV. https://www.osti.gov/biblio/960616. Colgate University, Hamilton, NY (United States), Accessed 15 Mar 2023

  34. Szklarczyk D et al (2021) The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res 49(D1):D605–D612. https://doi.org/10.1093/nar/gkaa1074

    Article  CAS  PubMed  Google Scholar 

  35. Valdeolivas A et al (2019) Random walk with restart on multiplex and heterogeneous biological networks. Bioinformatics 35(3):497–505. https://doi.org/10.1093/bioinformatics/bty637

    Article  CAS  PubMed  Google Scholar 

  36. Newman MEJ (2003) The structure and function of complex networks. SIAM Rev 45(2):167–256. https://doi.org/10.1137/s003614450342480

    Article  Google Scholar 

  37. Ahmed F et al (2022) Decade of bio-inspired soft robots: a review. Smart Mater Struct 31(7):073002. https://doi.org/10.1088/1361-665X/AC6E15

    Article  Google Scholar 

  38. Han N et al (2021) Identification of SARS-CoV-2–induced pathways reveals drug repurposing strategies. Sci Adv. https://doi.org/10.1126/SCIADV.ABH3032/SUPPL_FILE/ABH3032_TABLE_S9.XLSX

    Article  PubMed  PubMed Central  Google Scholar 

  39. Xie Z et al (2021) Gene set knowledge discovery with Enrichr. Curr Protoc 1(3):e90. https://doi.org/10.1002/CPZ1.90

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Huang DW et al (2007) The DAVID gene functional classification tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol 8(9):1–16. https://doi.org/10.1186/GB-2007-8-9-R183/TABLES/3

    Article  CAS  Google Scholar 

  41. Wishart DS et al (2006) DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 34(Database issue):D668. https://doi.org/10.1093/NAR/GKJ067

    Article  CAS  PubMed  Google Scholar 

  42. Kuhn M, von Mering C, Campillos M, Jensen LJ, Bork P (2008) STITCH: interaction networks of chemicals and proteins. Nucleic Acids Res. https://doi.org/10.1093/nar/gkm795

    Article  PubMed  PubMed Central  Google Scholar 

  43. Cheng F, István I, Kovácskovács A, László A-L, Lászlóbarabási L (2019) Network-based prediction of drug combinations. Nat Commun 10(1):1–11. https://doi.org/10.1038/s41467-019-09186-x

    Article  CAS  Google Scholar 

  44. Ahmed F et al (2022) Multi-material bio-inspired soft octopus robot for underwater synchronous swimming. J Bion Eng. https://doi.org/10.1007/S42235-022-00208-X

    Article  Google Scholar 

  45. Guney E, Menche J, Vidal M, Barábasi AL (2016) Network-based in silico drug efficacy screening. Nat Commun 7(May 2015):1–13. https://doi.org/10.1038/ncomms10331

    Article  CAS  Google Scholar 

  46. Wu Z, Peng Y, Yu Z, Li W, Liu G, Tang Y (2020) NetInfer: a web server for prediction of targets and therapeutic and adverse effects via network-based inference methods. J Chem Inf Model 60(8):3687–3691. https://doi.org/10.1021/ACS.JCIM.0C00291/SUPPL_FILE/CI0C00291_SI_002.XLSX

    Article  CAS  PubMed  Google Scholar 

  47. Oh MS, Chae YK (2019) Deep and durable response with combination CTLA-4 and PD-1 blockade in mismatch repair (MMR)-proficient endometrial cancer. J Immunother 42(2):51–54. https://doi.org/10.1097/CJI.0000000000000244

    Article  CAS  PubMed  Google Scholar 

  48. Friedman LA, Ring KL, Mills AM (2020) LAG-3 and GAL-3 in endometrial carcinoma: emerging candidates for immunotherapy. Int J Gynecol Pathol 39(3):203–212. https://doi.org/10.1097/PGP.0000000000000608

    Article  CAS  PubMed  Google Scholar 

  49. Singh MM, Singh E, Miller H, Strum WB, Coyle W (2012) Colorectal cancer screening in women with endometrial cancer: are we following the guidelines? J Gastrointest Cancer 43(2):190–195. https://doi.org/10.1007/S12029-011-9271-3

    Article  PubMed  Google Scholar 

  50. Visnyei K, Shahrokni A, Hashmi S, Orell J, Wild DMG (2012) A case of groans, moans and stones with malignant undertones: endometrioid carcinoma-associated hypercalcemia. Oncol Lett 3(2):335. https://doi.org/10.3892/OL.2011.475

    Article  PubMed  Google Scholar 

  51. Soisson S et al (2018) Long-term cardiovascular outcomes among endometrial cancer survivors in a large, population-based cohort study. J Natl Cancer Inst 110(12):1342. https://doi.org/10.1093/JNCI/DJY070

    Article  PubMed  PubMed Central  Google Scholar 

  52. Jin J, Dalwadi SM, Masand RP, Hall TR, Anderson ML, Ludwig MS (2020) Association between metabolic syndrome and endometrial cancer survival in a SEER-Medicare linked database. Am J Clin Oncol. https://doi.org/10.1097/COC.0000000000000686

    Article  PubMed  Google Scholar 

  53. Leskovec J, Krevl A (2014) Stanford large network dataset collection. https://snap.stanford.edu/data/. Accessed 15 Mar 2023

  54. Bastian M, Heymann S, Jacomy M (2009) Gephi: an open source software for exploring and manipulating networks. In: BT—international AAAI conference on weblogs and social. pp. 361–362

  55. Gaulton A et al (2012) ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res 40(Database issue):D1100. https://doi.org/10.1093/NAR/GKR777

    Article  CAS  PubMed  Google Scholar 

  56. Preto AJ, Matos-Filipe P, Mourão J, Moreira IS (2022) SYNPRED: prediction of drug combination effects in cancer using different synergy metrics and ensemble learning. GigaScience 11:1–15. https://doi.org/10.1093/GIGASCIENCE/GIAC087

    Article  CAS  Google Scholar 

  57. Foucquier J, Guedj M (2015) Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect 3(3):e00149. https://doi.org/10.1002/PRP2.149

    Article  PubMed  PubMed Central  Google Scholar 

  58. Ianevski A, Timonen S, Kononov A, Aittokallio T, Giri AK (2020) SynToxProfiler: an interactive analysis of drug combination synergy, toxicity and efficacy. PLoS Comput Biol 16(2):e1007604. https://doi.org/10.1371/JOURNAL.PCBI.1007604

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Lehár J et al (2009) Synergistic drug combinations improve therapeutic selectivity. Nat Biotechnol 27(7):659. https://doi.org/10.1038/NBT.1549

    Article  PubMed  PubMed Central  Google Scholar 

  60. Duarte D, Vale N (2022) Evaluation of synergism in drug combinations and reference models for future orientations in oncology. Curr Res Pharmacol Drug Discov 3:100110. https://doi.org/10.1016/J.CRPHAR.2022.100110

    Article  PubMed  PubMed Central  Google Scholar 

  61. Chen H, Zhang Z, Zhang J (2022) In silico drug repositioning based on integrated drug targets and canonical correlation analysis. BMC Med Genomics. https://doi.org/10.1186/S12920-022-01203-1

    Article  PubMed  PubMed Central  Google Scholar 

  62. Luo S, Lin R, Liao X, Li D, Qin Y (2021) Identification and verification of the molecular mechanisms and prognostic values of the cadherin gene family in gastric cancer. Sci Rep 11(1):23674. https://doi.org/10.1038/S41598-021-03086-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Brasky TM et al (2017) Nonsteroidal anti-inflammatory drugs and endometrial carcinoma mortality and recurrence. J Natl Cancer Inst. https://doi.org/10.1093/JNCI/DJW251

    Article  PubMed  PubMed Central  Google Scholar 

  64. Ando H et al (2017) Panobinostat enhances growth suppressive effects of progestin on endometrial carcinoma by increasing progesterone receptor and mitogen-inducible gene-6. Horm Cancer 8(4):257–267. https://doi.org/10.1007/S12672-017-0295-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Audrito V (2021) The extracellular NADome modulates immune responses. Front Immunol 12(August):17–20. https://doi.org/10.3389/fimmu.2021.704779

    Article  CAS  Google Scholar 

  66. Omran HM, Almaliki MS (2020) Influence of NAD+ as an ageing-related immunomodulator on COVID 19 infection: a hypothesis. J Infect Public Health 13(9):1196. https://doi.org/10.1016/J.JIPH.2020.06.004

    Article  PubMed  PubMed Central  Google Scholar 

  67. Xu X, Li X, Zhao Y, Huang H (2021) Immunomodulatory effects of histone deacetylation inhibitors in graft-vs.-host disease after allogeneic stem cell transplantation. Front Immunol 12:481. https://doi.org/10.3389/FIMMU.2021.641910/BIBTEX

    Article  Google Scholar 

  68. Díez-Tercero L, Delgado LM, Bosch-Rué E, Perez RA (2021) Evaluation of the immunomodulatory effects of cobalt, copper and magnesium ions in a pro inflammatory environment. Sci Rep 11(1):1–13. https://doi.org/10.1038/s41598-021-91070-0

    Article  CAS  Google Scholar 

  69. Ashraf Z et al (2019) Dexibuprofen amide derivatives as potential anticancer agents: synthesis, in silico docking, bioevaluation, and molecular dynamic simulation. Drug Des Dev Ther 13:1643. https://doi.org/10.2147/DDDT.S178595

    Article  CAS  Google Scholar 

  70. Yao W, Wang F, Wang H (2016) Immunomodulation of artemisinin and its derivatives. Sci Bull 61(18):1399–1406. https://doi.org/10.1007/S11434-016-1105-Z

    Article  CAS  Google Scholar 

  71. Mallat Z, Lobo SM, Malik A, Tong S (2021) 561. Phase 3 trial of fostamatinib for the treatment of COVID-19: repurposing an immunomodulatory drug previously approved for immune thrombocytopenia. Open Forum Infect Dis 8(Suppl 1):S382. https://doi.org/10.1093/OFID/OFAB466.759

    Article  Google Scholar 

  72. Migliorisi G et al (2022) Elexacaftor-tezacaftor-ivacaftor as a final frontier in the treatment of cystic fibrosis: definition of the clinical and microbiological implications in a case-control study. Pharmaceuticals. https://doi.org/10.3390/PH15050606

    Article  PubMed  PubMed Central  Google Scholar 

  73. Teng F et al (2016) Treatment with an SLC12A1 antagonist inhibits tumorigenesis in a subset of hepatocellular carcinomas. Oncotarget 7(33):53571–53582. https://doi.org/10.18632/oncotarget.10670

    Article  PubMed  PubMed Central  Google Scholar 

  74. Malebari AM et al (2020) The anticancer activity for the bumetanide-based analogs via targeting the tumor-associated membrane-bound human carbonic anhydrase-IX enzyme. Pharmaceuticals (Basel). https://doi.org/10.3390/ph13090252

    Article  PubMed  Google Scholar 

  75. Endo H, Yano M, Okumura Y, Kido H (2014) Ibuprofen enhances the anticancer activity of cisplatin in lung cancer cells by inhibiting the heat shock protein 70. Cell Death Dis 5(1):e1027. https://doi.org/10.1038/cddis.2013.550

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Shen W et al (2020) Ibuprofen mediates histone modification to diminish cancer cell stemness properties via a COX2-dependent manner. Br J Cancer 123(5):730–741. https://doi.org/10.1038/s41416-020-0906-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Helland Ø, Popa M, Bischof K, Gjertsen BT, McCormack E, Bjørge L (2016) The HDACi panobinostat shows growth inhibition both in vitro and in a bioluminescent orthotopic surgical xenograft model of ovarian cancer. PLoS ONE 11(6):e0158208. https://doi.org/10.1371/journal.pone.0158208

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Garrett LA, Growdon WB, Rueda BR, Foster R (2016) Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer. J Ovarian Res 9(1):58. https://doi.org/10.1186/s13048-016-0267-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Jeske R, Yuan X, Fu Q, Bunnell BA, Logan TM, Li Y (2021) In vitro culture expansion shifts the immune phenotype of human adipose-derived mesenchymal stem cells. Front Immunol 12:621744. https://doi.org/10.3389/fimmu.2021.621744

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Cheng M-H et al (2020) Prolonging the half-life of histone deacetylase inhibitor belinostat via 50 nm scale liposomal subcutaneous delivery system for peripheral T-cell lymphoma. Cancers (Basel). https://doi.org/10.3390/cancers12092558

    Article  PubMed  PubMed Central  Google Scholar 

  81. Shen Y et al (2022) The histone deacetylase inhibitor belinostat ameliorates experimental autoimmune encephalomyelitis in mice by inhibiting TLR2/MyD88 and HDAC3/NF-κB p65-mediated neuroinflammation. Pharmacol Res 176:105969. https://doi.org/10.1016/j.phrs.2021.105969

    Article  CAS  PubMed  Google Scholar 

  82. Llopiz D et al (2019) Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model. Cancer Immunol Immunother 68(3):379–393. https://doi.org/10.1007/s00262-018-2283-0

    Article  CAS  PubMed  Google Scholar 

  83. Cheng F et al (2022) Relationship between copper and immunity: the potential role of copper in tumor immunity. Front Oncol 12:1019153. https://doi.org/10.3389/fonc.2022.1019153

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Farsam V, Hassan ZM, Zavaran-Hosseini A, Noori S, Mahdavi M, Ranjbar M (2011) Antitumor and immunomodulatory properties of artemether and its ability to reduce CD4+ CD25+ FoxP3+ T reg cells in vivo. Int Immunopharmacol 11(11):1802–1808. https://doi.org/10.1016/j.intimp.2011.07.008

    Article  CAS  PubMed  Google Scholar 

  85. Li T et al (2012) Anti-inflammatory and immunomodulatory mechanisms of artemisinin on contact hypersensitivity. Int Immunopharmacol 12(1):144–150. https://doi.org/10.1016/j.intimp.2011.11.004

    Article  CAS  PubMed  Google Scholar 

  86. Park SR et al (2013) A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas. Cancer Chemother Pharmacol 71(4):981–990. https://doi.org/10.1007/s00280-013-2091-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Graeber S et al (2023) Effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis. Jahrestagung der Gesellschaft für Pädiatrische Pneumol. https://doi.org/10.1055/s-0043-1761569

    Article  Google Scholar 

  88. Samantasinghar A, Ahmed F, Rahim CSA, Kim KH, Kim S, Choi KH (2023) Artificial intelligence-assisted repurposing of lubiprostone alleviates tubulointerstitial fibrosis. Transl Res. https://doi.org/10.1016/j.trsl.2023.07.010

    Article  PubMed  Google Scholar 

  89. Fiscon G, Conte F, Farina L, Paci P (2022) A comparison of network-based methods for drug repurposing along with an application to human complex diseases. Int J Mol Sci. https://doi.org/10.3390/ijms23073703

    Article  PubMed  PubMed Central  Google Scholar 

  90. Fiscon G, Conte F, Farina L, Paci P (2021) SAveRUNNER: a network-based algorithm for drug repurposing and its application to COVID-19. PLoS Comput Biol 17(2):e1008686. https://doi.org/10.1371/JOURNAL.PCBI.1008686

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Zeng X et al (2020) Target identification among known drugs by deep learning from heterogeneous networks. Chem Sci 11(7):1775–1797. https://doi.org/10.1039/c9sc04336e

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Zeng X et al (2020) Network-based prediction of drug–target interactions using an arbitrary-order proximity embedded deep forest. Bioinformatics 36(9):2805–2812. https://doi.org/10.1093/BIOINFORMATICS/BTAA010

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Bedi O, Dhawan V, Sharma PL, Kumar P (2016) Pleiotropic effects of statins: new therapeutic targets in drug design. Naunyn Schmiedebergs Arch Pharmacol 389(7):695–712. https://doi.org/10.1007/S00210-016-1252-4

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by 2023 Jeju National University, South Korea.

Funding

This work was supported by 2023 Jeju National University, South Korea.

Author information

Authors and Affiliations

  1. Department of Mechatronics Engineering, Jeju National University, Jeju, Republic of Korea

    Faheem Ahmed, Anupama Samantasinghar, Wajid Ali & Kyung Hyun Choi

Authors
  1. Faheem Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anupama Samantasinghar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wajid Ali
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kyung Hyun Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

FA: conceptualization, formal analysis, methodology, original draft, writing—review & editing, data curation, and images. AS: conceptualization, formal analysis, writing—review & editing. WA: formal analysis, investigation, validation. KHC: conceptualization, review & editing, resources, supervision, funding acquisition.

Corresponding author

Correspondence to Kyung Hyun Choi.

Ethics declarations

Competing interests

The authors declare no competing interest of interest at this point.

Ethics approval and consent to participate

Will be provided on demand.

Consent for publication

The authors provide consent for publication.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ahmed, F., Samantasinghar, A., Ali, W. et al. Network-based drug repurposing identifies small molecule drugs as immune checkpoint inhibitors for endometrial cancer. Mol Divers (2024). https://doi.org/10.1007/s11030-023-10784-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11030-023-10784-7

Keywords

Search

Navigation